By blocking binding of VEGF and VEGFC to NRP2, these anti-NRP2B monoclonal antibodies decrease the number of tumor-associated lymphatic vessels and metastasis in sentinel lymph node and in distant organs in mice xenograft experiments [131]. Here, VEGFA is linked to neoplasm.